Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014

Alexandra L. Tabakin, Brian M. Shinder, Sinae Kim, Zorimar Rivera-Nunez, Charles F. Polotti, Parth K. Modi, Joshua A. Sterling, Nicholas J. Farber, Kushan D. Radadia, Rahul R. Parikh, Isaac Y. Kim, Biren Saraiya, Tina M. Mayer, Eric A. Singer, Thomas L. Jang

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

The role of retroperitoneal lymph node dissection (RPLND) as first-line treatment for stage I or IIA/B testicular seminoma is not well defined. Using the National Cancer Data Base, we identified 365 men from 2004 to 2014 who received RPLND as primary treatment for testicular seminoma and found 5-year overall survival rates of 97.3% and 92.0% for those with stage I and IIA/B disease, respectively.

Original languageEnglish
Pages (from-to)e194-e201
JournalClinical Genitourinary Cancer
Volume18
Issue number2
DOIs
StatePublished - Apr 2020
Externally publishedYes

Keywords

  • Outcomes
  • Overall survival
  • RPLND
  • Surgery
  • Testicular cancer

Fingerprint

Dive into the research topics of 'Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014'. Together they form a unique fingerprint.

Cite this